Mehraboon Irani of Nirmal Bang Securities remains negative on Ranbaxy. He says one should not buy the stock. "I don't see any reasons why Ranbaxy should be going up in a hurry at least from the present levels," he adds.
first published: May 30, 2013 04:51 pm
A collection of the most-viewed Moneycontrol videos.
Why This Tenant Says Bandra Is Better Than California | The Tenant
Nifty Clocks Triple-Digit Gains After RBI Rate Cut But Logs Losses For The Week| Closing Bell Live
LIVE: RBI Governor Sanjay Malhotra Delivers Key Monetary Policy Statement | Interest Rates & Outlook
Nifty’s Move Hinges On RBI Rate Decision; HUL, ITC Hotels In Focus| Opening Bell Live
